Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03291067 · ClinicalTrials.gov registry record · Phase 2
MT-8554 for Reduction of Vasomotor Symptoms in Postmenopausal Women
A Phase 2 study of Menopause Hot Flashes, sponsored by Tanabe Pharma America.
- Completed
- Registry status
- Phase 2
- Development phase
- 375
- Enrollment target
- 20
- Study locations
NCT03291067 is a Phase 2 study of Menopause Hot Flashes that has completed, run by Tanabe Pharma America. The registered enrollment target is 375 participants. The trial reports 20 study locations across 6 states.
The verdict
NCT03291067, a Phase 2 study of Menopause Hot Flashes, has completed, sponsored by Tanabe Pharma America.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 375 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the efficacy and safety of MT-8554 for treatment of vasomotor symptoms (VMS) associated with menopause.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG MT-8554 1mg
- DRUG MT-8554 5mg
- DRUG MT-8554 10mg
Study Locations (20)
Florida
- Research Site - Aventura
- Research Site - Clearwater
- Research Site - Crystal River
- Research Site - Fort Myers
- Research Site - Hialeah
- Research Site - Hialeah
- Research Site - Jacksonville
- Research Site - Jacksonville
- Research Site - Jupiter
- Research Site - Miami
- Research Site - Miami
California
- Research Site - Norwalk
- Research Site - Sacramento
- Research Site - San Diego
Alabama
- Research Site - Birmingham
- Research Site - Dothan
Connecticut
- Research Site - New London
- Research Site - New London
Arizona
- Research Site - Phoenix
Colorado
- Research Site - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 375 participants |
| Start Date | 2017-10-09 |
| Est. Completion | 2018-11-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03291067
The ClinicalTrials.gov registry entry for NCT03291067 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 375 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tanabe Pharma America, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Menopause Hot Flashes appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT03291067 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Florida, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT03291067 about?
NCT03291067 is a clinical study titled "MT-8554 for Reduction of Vasomotor Symptoms in Postmenopausal Women". The purpose of this study is to assess the efficacy and safety of MT-8554 for treatment of vasomotor symptoms (VMS) associated with menopause.
What is the current status of trial NCT03291067?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 375 participants. The study started on 2017-10-09. Estimated completion is 2018-11-09.
What conditions does trial NCT03291067 study?
This clinical trial studies the following conditions: Menopause Hot Flashes.
What interventions are being tested in trial NCT03291067?
The interventions under investigation include: Placebo (DRUG), MT-8554 1mg (DRUG), MT-8554 5mg (DRUG), MT-8554 10mg (DRUG).
Who is sponsoring clinical trial NCT03291067?
This trial is sponsored by Tanabe Pharma America, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03291067 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Menopause Hot Flashes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.